NCT01711034View on ClinicalTrials.gov

A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Solid Tumors
Interventions
DRUG

OPB-111077

"Dose escalation phase starting with dose of 100mg tablets on Day 1 and 4, and all remaining days of each 28 day cycle until disease progression or toxicity develops.~Dose expansion phase starting with daily dosing of 250mg for 28 day consecutive day cycles."

Trial Locations (1)

78229

San Antonio

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01711034 - A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer | Biotech Hunter | Biotech Hunter